![Zi Qiang Cheng](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Zi Qiang Cheng is the founder of Zion Pharma Ltd.
He currently holds the position of Chairman & Chief Executive Officer at the company, which was founded in 2018.
Zi Qiang Cheng active positions
Companies | Position | Start |
---|---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Chief Executive Officer | 2017-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Commercial Services |
- Stock Market
- Insiders
- Zi Qiang Cheng